Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 21:7:62.
doi: 10.1186/1746-6148-7-62.

Overexpression of α-enolase correlates with poor survival in canine mammary carcinoma

Pei-Yi Chu  1 , Nicholas C Hsu, Albert T Liao, Neng-Yao Shih, Ming-Feng Hou, Chen-Hsuan Liu
Affiliations

Overexpression of α-enolase correlates with poor survival in canine mammary carcinoma

Pei-Yi Chu et al. BMC Vet Res. .

Abstract

Background: α-Enolase (ENO1) is a key glycolytic enzyme implicated in the development of many human cancers including breast cancer. Increased expression of ENO1 has recently been reported in estrogen (ER)-positive human breast cancer patients. The present study examined the expression of ENO1 and assessed its significance in canine mammary carcinoma.

Results: Immunohistochemical staining was employed to investigate the expression of ENO1 in 82 cases of canine mammary tumor (32 benign tumors and 50 carcinomas). Quantification of immunohistochemistry was carried out using Quick score and the results showed cytoplasmic ENO1 overexpression in 9 of the 50 carcinomas (18%). Overexpression of ENO1 correlated significantly with shorter cause-specific survival (P = 0.019), but was not associated with ER positivity in canine mammary carcinoma.

Conclusions: Our findings suggest that overexpression of ENO1 may be used as a prognostic marker for poor outcome in canine mammary carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative figures of the immunohistochamical staining of ENO1 in (A) canine mammary carcinoma (Quick score = 12) and (B) benign tumor (Quick score = 0). Carcinoma cells showed strong cytoplasmic staining of ENO1 (400×).
Figure 2
Figure 2
ENO1 overexpression identified in tumor cells (blue arrow) and not adjacent non-tumor cells (red arrow) in a representative canine mammary carcinoma (400×).
Figure 3
Figure 3
Kaplan-Meier curves for cause-specific survival of canine mammary carcinoma patients with and without ENO1 overexpression. Sixteen of the fifty cases lacked survival data and were excluded from the analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cotchin E. Mammary neoplasms of the bitch. J Comp Pathol. 1958;68(1):1–22. - PubMed
    1. Moulton JE, Taylor DO, Dorn CR, Andersen AC. Canine mammary tumors. Pathol Vet. 1970;7(4):289–320. doi: 10.1177/030098587000700401. - DOI - PubMed
    1. Prier JE, Brodey RS. Canine Neoplasia. A Prototype for Human Cancer Study. Bull World Health Organ. 1963;29:331–344. - PMC - PubMed
    1. Gama A, Alves A, Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch. 2008;453(2):123–132. doi: 10.1007/s00428-008-0644-3. - DOI - PubMed
    1. Ferreira E, Gobbi H, Saraiva BS, Cassali GD. Columnar cell lesions of the canine mammary gland: pathological features and immunophenotypic analysis. BMC Cancer. 2010;10:61. doi: 10.1186/1471-2407-10-61. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources